<DOC>
	<DOCNO>NCT00303329</DOCNO>
	<brief_summary>A 1-year randomized Phase II core trial conduct investigate efficacy deferasirox regularly transfused patient β-thalassemia rare chronic anemia 2 year age old . Patients successfully complete main trial may continue extension trial receive chelation therapy deferasirox 3 year . Extension prolong 4 year . The objective study ass long-term safety efficacy deferasirox patient group .</brief_summary>
	<brief_title>Extension Study Iron Chelation Therapy With Deferasirox β-thalassemia Rare Chronic Anemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients complete planned 12month core study Female patient reach menarche sexually active must use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or ovariectomy , tubal ligation Written inform consent obtain patient and/or legal guardian patient 's behalf accordance national legislation Pregnant breast feeding patient Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>β-thalassemia</keyword>
	<keyword>rare chronic anemia</keyword>
	<keyword>iron overload</keyword>
	<keyword>deferasirox</keyword>
	<keyword>chronic anemia</keyword>
	<keyword>transfusional hemosiderosis</keyword>
</DOC>